SBIR Phase I: Sprayable hydrogel sealant for gastrointestinal wound protection
- Institution
- BIODEVEK INC, MA
- Principal investigator
- Gonzalo Munoz Taboada
- Funding
- $275K
- Duration
- 2023–2024
Moonbase score
Still being scored
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project centers on improving wound closure methods in minimally invasive procedures, such as endoscopy and robotic surgery. By harnessing innovative hydrogel technology based on biocompatible, biodegradable polymers, this project aims to establish a resilient barrier over surgical wounds and perforations. This transformative approach, devoid of cumbersome metal clips, promises to avert delayed bleeding, perforations, infections, and post-procedural complications. Initially designed for the gastrointestinal tract, the technology caters to unmet clinical needs, extending to applications in cardiovascular and lung sealing. The societal impact is evident in improved patient outcomes and reduced healthcare costs, while the commercial potential includes widespread adoption of a superior wound closure solution. This Small Business Innovation Research (SBIR) Phase I project focuses on the development of a versatile, sprayable sealant kit that delivers prolonged protection for gastrointestinal wounds. Employing multiple adhesion mechanisms, the technology ensures sustained adhesion across biological surfaces. Delivered via a catheter, it seamlessly integrates with commercial endoscopes and minimally invasive devices, optimizing surgical workflow. The project objectives involve the refinement of the adhesive formulation to meet gastrointestinal requirements and rigorous comparative testing. Anticipated technical outcomes encompass enhanced procedure efficiency, reduced complication rates, and improved wound healing, positioning this innovation as a transformative force in minimally invasive surgery. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
LOADING MOONBASE SCORE
Questions for Biodevek Inc
Biodevek Inc hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same researchers, same topic, scored first.
- NSF · Biodevek IncNot yet scored
SBIR Phase II: Sprayable Hydrogel Sealant for Gastrointestinal Wound Protection
Gonzalo Munoz Taboada · $1.3M · 2025–2027
- NSF · Ictero Medical, Inc.61
SBIR Phase II: High Surface Area (HSA) Intraluminal Cryoablation for the Treatment of High-Risk Patients with Gallstone Disease
Matthew Nojoomi · $967K · 2022–2026
- NIH · New York University School of Medicine46
Exosome treatment-induced mechanisms in chronic wound beds - Resubmission - 1
Piul Sanjana Rabbani · $162K · 2022–2026